SCHEMBL5694243

SCHEMBL5694243

Cc1c[nH]c(=O)nc1/N=C\N(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
THRB P10828 1/20 0.36
MAPT P10636 6/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
GAA P10253 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
ALOX15 P16050 1/20 0.34
RECQL P46063 1/20 0.34
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 2/20 0.34
POLB P06746 2/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5694245 1.00 LMNA (0.37) LMNAL3MBTL1MEN1KMT2ATHRB
SCHEMBL14104713 0.82 LMNA (0.36) LMNAL3MBTL1MEN1KMT2ATHRB
SCHEMBL1448418 0.82 LMNA (0.36) LMNAL3MBTL1MEN1KMT2ATHRB
SCHEMBL1448414 0.82 LMNA (0.36) LMNAL3MBTL1MEN1KMT2ATHRB
SCHEMBL15879553 0.74 ATAD2 (0.34)
SCHEMBL4016272 0.69
SCHEMBL5694201 0.68 LMNA (0.35) LMNAL3MBTL1MEN1KMT2AMAPT
SCHEMBL1335004 0.68 LMNA (0.35) LMNAL3MBTL1MEN1KMT2AMAPT
SCHEMBL15743183 0.67 MAT2A (0.37)
SCHEMBL31329939 0.66 KMT2A (0.38) L3MBTL1MEN1KMT2ATHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1645561-A1 METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2006-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB LMNA 321/4885L3MBTL1 398/4885MEN1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.